1. China Stocks

  2. •

    Health technology

  3. •

    Medical specialties
APT Medical Inc. Class A

APT Medical Inc. Class A

SSSE:688617
268.00
CNY
+10.12
(+3.92%)
6.82EPS
26.06P/E
25.70BMarket Cap
Oct 29Next Earn
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.46
2.3
3.84
4.57
6.05
8.69
11.81
14.73
18.33
20.63
Basic EPS, GAAP
0.33
0.2
0.78
1.06
1.52
2.56
3.82
4.8
5.82
6.97
Free Cash Flow per Basic Share
-0.12
-0.13
-0.12
0.99
0.1
1.6
3.49
0.66
4.84
- -
Dividend per Share
- -
- -
0.06
0.01
0.24
0.49
0.8
0.96
1.21
2.21
Book Value per Share
2.04
2.57
3.33
4.38
12.69
12.58
13.57
17.82
21.9
21.81
Tangible Book Value per Share
2.03
2.56
2.34
4.07
12.45
12.3
12.63
14.63
18.79
18.77
Basic Weighted Avg Shares
105
105
105
105
137
140
140
140
141
140
Sales/Revenue/Turnover
153
242
404
479
829
1,216
1,650
2,066
2,584
2,892
Operating Margin (%)
10.3
9.37
23.43
25.07
24.12
31.97
34.99
36.55
36.56
38.54
Depreciation Expense
8
9
15
20
33
48
65
87
111
- -
Net Income, GAAP
34
22
83
111
208
358
534
673
821
977
Effective Tax Rate (%)
12.62
28.16
14.54
14.04
12.05
13.91
12.45
11.77
13.73
12.71
Profit Margin (%)
22.51
8.9
20.44
23.11
25.09
29.44
32.35
32.59
31.76
33.77
Working Capital
126
159
173
237
1,359
1,146
1,168
1,211
1,663
1,608
LT Debt
- -
- -
104
28
17
9
9
5
12
5
Total Equity
214
271
346
450
1,791
1,791
1,962
2,555
3,130
3,120
Return on Invested Capital (%)
- -
6.8
20.55
20.8
16.66
18.43
26.72
28.48
28.22
32.33
Return on Capital (%)
- -
10.69
22.82
24.07
19.05
20.49
28.18
29.88
29.21
33.79
Return on Common Equity (%)
- -
8.89
26.66
27.35
18.58
20.22
29.09
30.44
29.28
33.75

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
8
8
9
LT Borrowings
4
- -
- -
LT Finance Leases
8
7
5
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
141
141
142
Market Capitalization
34,308
35,259
25,696

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
2,122
1,882
2,046
Cash, Cash Equivalents & STI
1,515
1,291
1,424
Accounts Receivable, Net
78
58
76
Inventories
492
480
493
Total Current Liabilities
459
362
438
Payables & Accruals
- -
- -
- -
ST Debt
8
8
9
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
22.53%
Free Cash Flow
- -
416.54%
632.37%
Net Income, GAAP
- -
51.4%
21.91%
Sales/Revenue/Turnover
- -
41.11%
25.08%
Total Cash Common Dividend
- -
493.22%
27.1%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
455
546
524
541
2,066
2025
564
650
- -
716
2,584
2026
704
822
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1
1.44
1.32
1.05
4.8
2025
1.3
1.72
- -
1.4
5.82
2026
1.64
2.21
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
0.95
- -
0.96
2025
- -
1.21
- -
- -
1.21
2026
- -
1
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Zheng Hui Cheng
Full Time Employees
3,118
Sector
Health technology
Industry
Medical specialties
Address
Building B, Tongfang Information Port Shenzhen GD China 518000
IPO Date
Jan 7, 2021
Website
aptmed.com
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
APT Medical Inc. (688617.SS) develops, manufactures and markets electrophysiology and vascular interventional medical devices for cardiovascular procedures in China and internationally. The company provides electrophysiological products including mapping catheters, ablation catheters, transseptal needles and sheaths, steerable sheaths; interventional cardiology and peripheral intervention products such as introducer kits, guiding extension catheters, balloon catheters, guiding catheters, microcatheters, guidewires, hydrophilic angiographic catheters, hydrophilic guidewires, hemostasis introducers, radial compression devices, aspiration catheters, inflation devices, Y connectors, snare kits, hemostasis valves, L guiding sheaths, balloon occlusion microcatheters, embolic protection devices, transjugular liver access sets and steerable guiding sheaths; and neurointervention devices, alongside OEM/ODM services encompassing project design, development, customization and volume production. Founded in 2002 and headquartered in Shenzhen, China, APT Medical operates primarily in the healthcare sector with approximately 2,155 employees and serves clinicians, hospitals and academic institutions across electrophysiology, cardiology, peripheral and neurointervention segments in over 30 countries. In 2024, Mindray Bio-Medical Electronics announced a $927 million deal to acquire a 21.12% controlling stake in APT Medical from existing shareholders, aiming to leverage Mindray's global sales network for expanded international reach and integrate equipment with APT's consumables for cardiovascular treatments. Recently in 2025, APT Medical achieved milestones including the first pulsed-field ablation procedures with its 3D mapping platform in Indonesia and showcased innovations like AForcePlus PFA catheters and HT Viewer 3D Mapping System at events such as EuroPCR 2025 and expert exchanges at Beijing Anzhen and Fuwai Hospitals, highlighting expansions in complex PCI and arrhythmia treatments.